Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Vera Therapeutics, Inc. | Director | Class A Common Stock | 2.99K | $129K | $43.03 | Jun 7, 2024 | Direct |
Karyopharm Therapeutics Inc. | Director | Nonstatutory Stock Option (right to buy) | 69K | May 29, 2024 | Direct | ||
Replimune Group, Inc. | Director | Stock Option (right to buy) | 32K | Apr 1, 2024 | Direct | ||
Vera Therapeutics, Inc. | Director | Stock Option (right to buy) | 25K | Jun 7, 2024 | Direct | ||
RayzeBio, Inc. | Director | Employee Stock Option (Right to Buy) | 0 | Feb 26, 2024 | Direct | ||
REATA PHARMACEUTICALS INC | Director | Class A common stock | 0 | $172.03 | Sep 26, 2023 | Direct | |
REATA PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 0 | Sep 26, 2023 | Direct | ||
Sierra Oncology, Inc. | Director | Stock Option (right to buy) | 0 | Jul 1, 2022 | Direct |